It's not the most prominent biotech, but it has an important claim to fame. Madrigal Pharmaceuticals' (MDGL -0.79%) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezdiffra, a therapy for non-alcoholic steatohepatitis (NASH). Not only was Rezdiffra Madrigal's first product on the market, but it is also the first and only approved by the U.S. Food and ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Eli Merle - UBS Liisa Bayko - Evercore Jay Olson - Oppenheimer Ritu Baral - TD Cowen Thomas Smith - Leerink Partners Akash Tewari - Jefferies Jon Wolleben - Citizens Andrea Tan - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to Madrigal Pharmaceutical ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Table of Contents OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 _________________________ MADRIGAL PHARMACEUTICALS, INC. (Exact name of regis ...

Exhibit 99.1 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., May 7, 2024 – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Madrigal is the first company to deliver an approved therapy for pa ...

mikkelwilliam Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) achieved history in March by garnering US FDA approval for Rezdiffra (resmetirom), the first drug specifically indicated for nonalcoholic steatohepatitis (NASH). On April 9, 2024, MDGL announced the availability of Rezdiffra meaning the launch of this first-to-market drug is now underway. In this article, I consider the prospects of the drug and the expectations I think the market might have. The approval and the market MDGL's Rezdiffra is approved ...

CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen's family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent innovations an ...

Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results CONSHOHOCKEN, PA, February 28, 2024 – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports fourth quarter and full year 2023 financial results. Bill Sibold, Chief Executive Officer of Madrigal, stated "As we approach the ...

Table of Contents UNITEDSTATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 10-K _______________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________ Commission file number: 001-33277 _______________________ MADRIGAL PHARMACEUTI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3508648 (State or o ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3508648 (State or other ...